Evidence map›Paper›PMID 39113118›Full record

ReviewCardio-oncology (London, England)2024

Crosslink between atrial fibrillation and cancer: a therapeutic conundrum.

Ermanno Nardi, Ciro Santoro, Maria Prastaro, Mario Enrico Canonico, Stefania Paolillo, Giuseppe Gargiulo, Paola Gargiulo, Antonio L M Parlati, Christian Basile, Luca Bardi and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardio-oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Cancer, Inflammation, and Thrombosis: Drivers of Atrial Fibrillation in Oncology Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ermanno NardiDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Ciro SantoroDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. ciro.santoro@unina.it.
Maria PrastaroDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Mario Enrico CanonicoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Stefania PaolilloDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Giuseppe GargiuloDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Paola GargiuloDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Antonio L M ParlatiDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Christian BasileDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Luca BardiDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Mario GiulianoDepartment of Clinical Medicine and Surgery, University Federico II Rare Tumors Coordinating Center of Campania Region (CRCTR), Naples, Italy.
Giovanni EspositoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation (AF) is more common in patients with malignancies than in general population. The pathophysiological processes include the pro-inflammatory condition and the exaggerated inflammatory reaction to chemotherapy, radiotherapy, and surgery interventions. Thus, it is pivotal to decrease morbidity and mortality in this group by providing appropriate care and prevention. In this subset, the risk of thromboembolic and bleeding events is high and the common risk score such as CHA2DS2-VASc and HAS-BLED employed in non-oncologic patients have limited evidence in cancer patients. A paucity of evidence in the setting in individuals having both malignancies and atrial fibrillation entangle the clinician when it comes to therapeutic management. Tailored management is recommended of anticoagulation treatment could be difficult, and there is. In this review, we try to explain the mechanism of AF in cancer patients as well as its management in this setting.

Indexed as

AnticoagulantsAtrial fibrillationCancerCardio-oncologyCardiotoxicity

Identifiers

PMID39113118
PMCPMC11304574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.